MarketPulse

clinical-stage biotechnology

8 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

INmune Bio to Unveil Q1 2026 Results Amid Clinical-Stage Immunology Development

$INMB will report Q1 2026 financials May 7th, providing updates on its three immunology product platforms targeting inflammation and innate immune disorders.
INMBconference callclinical-stage biotechnology
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Jade Biosciences Names Chief Medical Officer, Awards $12.7M Stock Option Grant

Clinical-stage biotech Jade Biosciences appoints Dr. Edward Conner as CMO, grants 500,000 stock options valued at $12.7M as inducement under Nasdaq rules.
JBIOautoimmune diseasesclinical-stage biotechnology
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Adlai Nortye Raises $150M in Oversubscribed Private Placement to Fund Cancer Pipeline

$ANL raises $150M from institutional investors including Soleus Capital and Perceptive Advisors to advance RAS-targeting and cancer immunotherapy programs.
ANLinstitutional investorsprivate placement
GlobeNewswire Inc.GlobeNewswire Inc.··Ataibeckley Inc.

AtaiBeckley CEO to Present at Needham Conferences as Psychedelic Drug Advances

AtaiBeckley will showcase its FDA-designated breakthrough therapy BPL-003 at Needham conferences in April, advancing toward Phase 3 trials in 2026.
ATAItreatment-resistant depressionFDA Breakthrough Therapy Designation
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Eupraxia Raises $63.2M, Eyes 2028 as Cash-Runway Extends Despite Rising Losses

Eupraxia Pharmaceuticals closed $63.2M offering, boosting cash to $80.5M with runway through H2 2028. Q4 losses doubled to $16.7M amid clinical progress in eosinophilic esophagitis treatment.
EPRXpublic offeringdrug delivery
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Upstream Bio to Present Pipeline Progress at Major Healthcare Conferences

Upstream Bio will present pipeline progress at two March 2026 healthcare conferences, discussing its TSLP receptor antagonist in Phase 2 trials for severe respiratory conditions.
UPBinvestor conferenceverekitug
The Motley FoolThe Motley Fool··Jonathan Ponciano

Perceptive Advisors Doubles Down on Celcuity as Stock Ascends 700% YoY

Perceptive Advisors doubled its Celcuity stake to 5.62% of AUM, making it the fund's second-largest holding. Stock surged 700% YoY ahead of expected FDA approval for lead drug Gedatolisib.
CELCFDA approvalbiotech
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Protara Therapeutics to Present TARA-002 Data at Major Medical Conferences

Protara Therapeutics will present TARA-002 Phase 2 interim data at ASCO GU Symposium, showcasing results for BCG-unresponsive bladder cancer treatment.
TARAinvestor conferencebladder cancer